Avanos Medical, Inc. (AVNS) Stock Analysis

Avanos Medical, Inc. (AVNS) Healthcare & Pipeline Overview

Avanos Medical, Inc. is a medical technology company delivering chronic care and pain management solutions globally. Its portfolio includes digestive and respiratory health products, alongside non-opioid pain relief therapies, positioning it as a key player in the medical device sector with a focus on innovation and direct sales.

What Is the Investment Thesis for AVNS?

Avanos Medical, Inc. presents a mixed investment thesis. The company's focus on non-opioid pain management solutions aligns with a growing market demand, potentially driving revenue growth. The company's gross margin of 49.4% indicates solid pricing power. However, the company's negative profit margin of -9.7% raises concerns about profitability and cost management. Key catalysts include expansion of the Coolief pain relief therapy and increasing adoption of its chronic care products. Investors should monitor the company's ability to improve profitability and manage its operating expenses. The beta of 1.09 suggests that the stock's volatility is similar to the market average.

Based on FMP financials and quantitative analysis

AVNS Key Highlights

Market Cap of $1.17B reflects its current valuation in the medical device market.

• Gross Margin of 49.4% indicates solid pricing power and efficient cost management in product manufacturing.
• Profit Margin of -9.7% highlights challenges in achieving profitability and managing operating expenses.
• Beta of 1.09 suggests the stock's volatility is similar to the market average.
• Focus on non-opioid pain management solutions aligns with a growing market demand, potentially driving revenue growth.

Who Are AVNS's Competitors?

AVNS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AVNS's Key Strengths?

Strong portfolio of chronic care and pain management products.

• Established distribution network.
• Focus on innovation and patient outcomes.
• Proprietary technologies in key product areas.

What Are AVNS's Weaknesses?

Negative profit margin.

• Reliance on third-party distributors.
• Limited presence in emerging markets compared to larger competitors.
• Exposure to regulatory risks and product liability claims.

What Could Drive AVNS Stock Higher?

Expansion of the Coolief pain relief therapy into new markets and clinical applications.

• Increasing adoption of chronic care products, driven by the growing geriatric population and rising incidence of chronic diseases.
• Strategic partnerships to expand market reach and product offerings.

What Are the Key Risks for AVNS?

Negative return on equity (-8.9%) — the business is not currently generating profit on shareholder capital.

• Insider selling — insiders were net sellers of roughly $25.9M recently.
• Intense competition from larger medical device companies.
• Pricing pressures from healthcare providers and payers.
• Regulatory changes and product recalls.
• Economic downturns and healthcare spending cuts.

What Are the Growth Opportunities for AVNS?

• Expansion of Coolief Pain Relief Therapy: Avanos has the opportunity to expand the market reach of its Coolief pain relief therapy, a minimally invasive, non-opioid treatment for chronic pain. The market for interventional pain management is growing, driven by an aging population and increasing prevalence of chronic pain conditions. Successful expansion could significantly boost revenue within the next 3-5 years.
• Increased Adoption of Chronic Care Products: Avanos can drive growth by increasing the adoption of its chronic care products, including Mic-Key enteral feeding tubes and Corpak patient feeding solutions. The market for enteral feeding solutions is expanding due to the rising incidence of chronic diseases and the growing geriatric population. Focus on innovation and strategic partnerships can enhance market penetration.
• Geographic Expansion: Avanos has the opportunity to expand its presence in emerging markets, particularly in the Asia Pacific and Latin America. These regions offer significant growth potential due to their large populations and increasing healthcare spending. Strategic partnerships and targeted marketing efforts can facilitate successful market entry and expansion.
• Strategic Acquisitions: Avanos can pursue strategic acquisitions to expand its product portfolio and market reach. Acquiring companies with complementary technologies or products can enhance its competitive position and drive revenue growth. Careful due diligence and integration are essential for successful acquisitions.
• Development of Innovative Products: Avanos can invest in research and development to develop innovative medical device solutions that address unmet clinical needs. Focus on areas such as remote patient monitoring, personalized medicine, and minimally invasive procedures can drive long-term growth and create a competitive advantage.

What Are AVNS's Competitive Advantages?

• Proprietary Technology: Avanos has proprietary technologies in its pain management and chronic care products, creating a barrier to entry for competitors.
• Established Brand Reputation: Avanos has built a strong brand reputation for quality and reliability, fostering customer loyalty.
• Distribution Network: Avanos has an established distribution network, including direct sales and third-party distributors, providing broad market access.
• Regulatory Expertise: Avanos has expertise in navigating the complex regulatory landscape for medical devices, providing a competitive advantage.

What Does AVNS Do?

Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia. Formerly known as Halyard Health, Inc., the company rebranded in June 2018 to Avanos Medical, Inc. The company develops, manufactures, and markets medical device solutions focused on chronic care and pain management. Avanos operates across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Its chronic care product line includes digestive health products like Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The respiratory health products include closed airway suction systems and airway management devices under the Ballard, Microcuff, and Endoclear brands. In non-opioid pain solutions, Avanos offers acute pain products such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems, and interventional pain solutions like Coolief pain relief therapy. Avanos markets its products directly to hospitals, healthcare providers, facilities, and end-users, as well as through third-party wholesale distributors, ensuring broad market access and customer reach. The company's focus is on innovation and patient outcomes.

What Products and Services Does AVNS Offer?

• Develops and markets medical device solutions.
• Offers chronic care products, including digestive and respiratory health devices.
• Provides non-opioid pain management solutions.
• Markets products directly to hospitals and healthcare providers.
• Distributes products through third-party wholesalers.
• Focuses on innovation and patient outcomes.

How Does AVNS Make Money?

• Develops and manufactures medical devices.
• Sells products directly to hospitals and healthcare providers.
• Utilizes third-party distributors to reach a broader market.
• Generates revenue through product sales and service contracts.

What Industry Does AVNS Operate In?

Avanos Medical, Inc. operates in the medical device industry, which is characterized by continuous innovation, stringent regulatory requirements, and increasing demand for advanced healthcare solutions. The market for non-opioid pain management is growing due to concerns about opioid addiction. The competitive landscape includes both large, diversified medical device companies and smaller, specialized players. Avanos' focus on specific niches like chronic care and non-opioid pain relief helps it to differentiate itself. The industry is also influenced by trends such as telemedicine, remote patient monitoring, and personalized medicine.

Who Are AVNS's Key Customers?

• Hospitals and healthcare facilities.
• Healthcare providers, including physicians and nurses.
• End-user patients requiring chronic care or pain management.
• Third-party wholesale distributors.

Company Profile

Avanos Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Alpharetta, US. The company is led by CEO David C. Pacitti. AVNS has traded publicly since 2014.

Avanos Medical, Inc. Financial Trajectory

Avanos Medical, Inc. (AVNS) reported $182.2M in revenue for Q1 FY2026, reflecting 0.7% growth compared to the prior quarter. The company recorded net income of $5.1M, with diluted EPS of $0.11. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, AVNS averaged $-0.37 in diluted EPS.

How Avanos Medical, Inc. Is Valued

Avanos Medical, Inc. carries a market capitalization of $1.17B, placing it in the small-cap category.

Return on equity for Avanos Medical, Inc. stands at -8.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.0%, the inverse of the P/E and a quick read on earnings relative to price.

Avanos Medical, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.30 places it in the grey zone, a middle ground that warrants monitoring.

Avanos Medical, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 24.7% above estimates on average.

Over the past six months, Avanos Medical, Inc. insiders filed 29 SEC Form 4 transactions — 21 sales and 8 purchases. On net that is roughly 622K shares disposed (about $25.9M), a signal worth weighing alongside the fundamentals.

AVNS Financials

AVNS Latest News

Common Questions About AVNS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources